The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results.
Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance - many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians.
The fifth volume brings together reviews on the following topics:
Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance - many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians.
The fifth volume brings together reviews on the following topics:
- Targeted therapy for tumor vasculature
- Anti-angiogenic therapy for breast and prostate cancers (including information updates on clinical trials)
- Microbe-based and other novel antiangiogenesis therapies, including chromene-based agents
Table of Contents
Chapter 1 Therapeutic Targeting of the Tumor Vasculature: Past,- Present and Future
- Peace Mabeta, Mike Sathekge and Vanessa Steenkamp
- Introduction
- Angiogenesis in Tumor Progression
- The Tumor Vasculature
- Importance of Vascular Endothelial Growth Factor Signaling in Cancer
- Therapeutic Targeting of Vascular Endothelial Growth Factor
- Beyond Bevacizumab
- Ramucirumab
- Apatinib
- Effectiveness of Anti-Vegf Versus Anti-Vegfr Therapy
- Development of Resistance to Vegf/Vegfr-2 Targeting Drugs
- Platelet-Derived Growth Factor Pathway
- Fibroblast Growth Factor Signaling in Anti-Cancer Therapy
- Angiopoietin-Tie Pathway in Therapeutic Anti-Angiogenesis
- Therapeutic Targeting of Multiple Angiogenic Pathways
- Multi-Targeting Tyrosine Kinase Inhibitors
- Sorafenib
- Sunitinib
- Axitinib
- Pazopanib
- Nintedanib
- Multi-Targeting Versus Mono-Targeting Ais
- Fusion Peptides and Decoy Receptors
- Aflibercept
- Abexinostat and Panobinostat Attenuate Hypoxia
- Immune Cells and the Effectiveness of Angiogenesis Inhibitors
- Overcoming Inflammation - Angiogenesis Inhibitors And
- Immunotherapy
- Normalization of the Tumor Vasculature
- Future Perspective - Imaging Biomarkers in Angiogenesis
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 2 Anti-Angiogenic Mechanism, Biochemical Factors’ Roles,
- Therapeutic Agents, and Under Clinical Trial Drugs for Breast And
- Prostate Cancers
- Varsha M. Singh, Shilpa J. Newati, Mohammad Yusuf, Alexandre Bridoux, Salman,
- A. A. Mohammed, Naseem Akhtar and Riaz A. Khan
- Introduction: The Angiogenesis and Cancers
- Angiogenic Biomechanisms: Normal Versus Tumor-Induced
- Tumor Vasculature
- Operational Signaling Pathways in Tumor
- Angiogenic Promoters and Their Involvement in Breast Cancer
- Angiogenin
- Vascular Endothelial Growth Factors (Vegfs)
- Interleukins
- Fibroblast Growth Factors (Fgf)
- Matrix Metalloproteinases (Mmps) and Matrix Remodeling
- Angiopoietins
- Roles of Integrins in Tumorigenesis
- Angiogenic Inhibitors
- Interferons
- Endostatin
- Angiostatin
- Thrombospondin
- Decorin
- Commercially Aailable Angiogenic Inhibitors
- Clinical Trials Towards Anti-Angiogenic Drugs Development
- Bevacizumab
- Cilengitide
- Aflibercept
- Ramucirumab
- Sorafenib
- Sunitinib
- Vandetanib
- Axitinib
- Pazopanib
- Drugs Approved to Treat Breast Cancers
- Relationship Between Inflammation, Angiogenesis, And
- Coagulation in Prostate Cancers
- Angiogenesis, Thrombosis and Inflammation Mediators’ Crosstalk
- Angiogenesis and Inflammation Mediators’ Crosstalk
- Angiogenic Capability of Tumors and Thromboembolic Crosstalk
- Clinical Trials for Anti-Angiogenic Prostate Cancer Drug
- Development
- Use of Antiangiogenic Agents in Prostate Cancer
- Thalidomide
- Bevacizumab
- Vegf Trap
- Tyrosine Kinase Inhibitors (Tki)
- Usfda Approved Drugs for Prostate Cancer
- Conclusions
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 3 Microbe-Based Antiangiogenesis Therapies for Cancer
- Management
- Samman Munir, Usman Ali Ashfaq, Asad Ali Shah, Muhammad Shahid, Muhammad,
- Sajid Hamid Akash and Mohsin Khurshid
- Introduction
- Tumor Angiogenesis
- Tumor Microenvironment
- Vascular Normalization
- Basis of Anti-Angiogenesis Therapy
- Current Antiangiogenic Agents
- Gene Therapy Using Angiogenesis Inhibitors
- Angiostatin
- Tumstatin
- Endostatin
- Interleukin-12 (Il-12)
- Nk4
- Metargidin Peptide
- Endoglin
- Inherent Resistance Against Antiangiogenic Therapy
- Bacteria as Tumoricidal Agents
- Bacteria Mediated Anti-Angiogenesis Gene Therapy
- B
- Techniques for the Use of Modified Bacteria as Anticancer
- Therapeutics
- Bactofection
- Rna Interference
- Dna Vaccination
- Alternative Gene Therapy (Agt)
- Conclusion and Future Prospects
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 4 Novel Anti-Angiogenic Strategies in Cancer Drug
- Development
- Hoorieh Soleimanjahi and Ala Habibian
- Introduction
- Angiogenesis Stimulator Factors and Receptors
- Angiogenesis Inhibition
- Role of Angiogenesis and Anti-Angiogenesis Signaling Pathways
- Targeting Angiogenesis for Cancer Therapy by Mesenchymal Stem Cells
- Evidence for Anti Tumoral Potency of Mscs
- Role of Mscs as an Angiogenic Agent
- Emerging Extracellular Vesicles
- Virotherapy and Oncolytic Viruses
- Oncolytic Herpes Simplex Virus
- Oncolytic Reovirus
- Oncolytic Adenovirus
- Mscs Loading Oncolytic Viruses
- Conclusion and Future Perspective
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
- Olívia Pontes, Ana Raquel-Cunha, Sofia Oliveira-Pinto, Fátima Baltazar, Olga,
- Martinho and Marta Costa
- Introduction
- Angiogenesis Overview
- Angiogenesis in Cancer
- Antiangiogenic Therapies in Cancer
- Chromene-Based Compounds
- Natural Chromenes as Angiogenesis Inhibitors
- Derivatives of Natural Chromenes as Angiogenesis Inhibitors
- Synthetic Chromenes as Angiogenesis Inhibitors
- Conclusion
- Consent for Publication
- Conflict of Interest
- Acknowledgements
- References
Chapter 5 Angiogenesis and Chromene-Based Antiangiogenic
- Therapeutic Agents
- Subject Index
Author
- Atta-ur-Rahman
- M. Iqbal Choudhary
